A new study published in the journal Cell Cycle, and published online by the National Institute of Health, has found that cannabis may provide a treatment option for thrombocytopenia-related diseases. Thrombocytopenia is any disorder in which there is an abnormally low amount of platelets.
For the study, researchers “sought to further interrogate the role of 2-AG [a synthetic cannabinoid] in megakaryocyte/platelet physiology by investigating terminal differentiation, and subsequent thrombopoiesis… To this end, we used MEG-01 cells, a human megakaryoblastic cell line able to produce in vitro platelet-like particles.”
After conducting the study, researchers conclude that cannabinoids, by triggering megakaryocyte maturation and platelet release, “may have clinical efficacy to counteract thrombocytopenia-related diseases.”
The study was conducted by researchers at the Department of Experimental Medicine & Surgery at the University of Rome Tor Vergata, and can be found by clicking here.